Health Care & Life Sciences » Pharmaceuticals | Chengdu Kanghong Pharmaceutical Group Co. Ltd.

Chengdu Kanghong Pharmaceutical Group Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,451
1,646
2,074
2,494
2,739
2,873
Cost of Goods Sold (COGS) incl. D&A
202
212
244
261
285
256
Gross Income
1,249
1,434
1,830
2,233
2,454
2,617
SG&A Expense
943
1,113
1,376
1,714
1,770
1,966
EBIT
298
310
423
517
680
648
Unusual Expense
-
-
-
-
-
-
Non Operating Income/Expense
18
8
9
5
19
80
Interest Expense
-
1
-
2
1
1
Pretax Income
322
338
456
568
763
800
Income Tax
53
61
59
68
119
105
Equity in Affiliates
50
-
-
-
-
1
Consolidated Net Income
319
276
397
500
644
695
Net Income
316
273
394
497
644
695
Net Income After Extraordinaries
316
273
394
497
644
695
Net Income Available to Common
316
273
394
497
644
695
EPS (Basic)
0.53
0.45
0.59
0.74
0.96
0.79
Basic Shares Outstanding
668
668
668
669
671
876
EPS (Diluted)
0.47
0.41
0.59
0.74
0.95
0.79
Diluted Shares Outstanding
668
668
668
675
678
877
EBITDA
358
380
495
589
753
729
Other Operating Expense
9
11
31
2
3
3
Non-Operating Interest Income
9
20
24
36
65
72
Minority Interest Expense
3
3
3
3
-
-

About Chengdu Kanghong Pharmaceutical Group Co.

View Profile
Address
No. 36 Shuxi Road
Chengdu Sichuan 610036
China
Employees -
Website http://www.cnkh.com
Updated 07/08/2019
Chengdu Kanghong Pharmaceutical Group Co., Ltd. engages in the research, manufacture and distribution of biological products, traditional Chinese medicines, and chemical drugs. Its products include conbercept ophthalmic injection, songling xuemaikang jiaonang, shugan jieyu jiaonang, kenuoxin jiaonang, danshu jiaonang, yiqing jiaonang, venlafaxine hydrochloride capsules and sustained-release tablets, aripiprazole tablets and orally disintergrating tablets, mosapride citrate dispersible tablets, and dexzopiclone tablet. The company was founded on October 3, 1996 and is headquartered in Chengdu, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.